trending Market Intelligence /marketintelligence/en/news-insights/trending/ZXqg-IRk1UU1eB94YdbIWw2 content esgSubNav
In This List

Lexicon's Zynquista helps treat type 2 diabetes in late-stage study

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Lexicon's Zynquista helps treat type 2 diabetes in late-stage study

Lexicon Pharmaceuticals Inc.'s diabetes drug Zynquista beat placebo and matched Eli Lilly and Co.'s Jardiance in reducing blood sugar levels of certain patients with type 2 diabetes in a late-stage study.

The Sota-Empa multicenter study compared the effectiveness of Zynquista, placebo and empagliflozin, sold by Lilly and Boehringer Ingelheim GmbH under brand name Jardiance, on 700 patients over a 26 week period.

Patients in the study had inadequate sugar metabolism from type 2 diabetes, despite using a class of oral drugs known as Dipeptidyl peptidase-4 inhibitors, which help preserve a group of hormones that decrease glucose levels in the blood.

The company expects top-line results from its remaining late-stage studies of Zynquista in early 2020, Lexicon's executive vice president and chief medical officer, Pablo Lapuerta, said in a statement.

Zynquista, or sotagliflozin, was approved by the European Commission in April as an add-on therapy for adults with type 1 diabetes. In contrast, the U.S Food and Drug Administration rejected it for the same treatment and denied the Woodlands, Texas-based company's appeal over the rejection.